Navigation Links
Toward understanding the dangers of the fake marijuana called 'Spice' or 'K2'
Date:10/2/2013

The harmful effects of increasingly popular designer cannabis products called "Spice" or "K2" have puzzled scientists for years, but now a group of researchers is reporting progress toward understanding what makes them so toxic. The study, published in the ACS journal Analytical Chemistry, describes development of a method that could someday help physicians diagnose and treat the thousands of young adults and teens who end up in emergency rooms after taking the drugs.

Jeffery Moran and colleagues note that synthetic marijuana, often marketed as "natural incense," "potpourri," Spice or K2, is a significant public health concern, and 1 in 9 high school seniors admit recent use. The products appear across the United States and Europe, and are the second most popular drug after real marijuana for many American teens and young adults. The substances produce a "high," but also can cause a wide range of dangerous side effects including seizures, hallucinations, severe kidney damage, psychotic behavior and heart attacks. Scientists are quickly playing catch-up to understand how these fake pot products work in order to identify them in users' urine and to treat the devastating health effects, which, in some cases, plague users for months after they initially take it.

To gain insight into the effects of designer marijuana products, Moran's team developed a new method and used it to study how the body processes two popular forms in Spice and K2, known as JWH-018 and AM2201. Urine samples from 15 people who tested positive for use showed significant differences in how the individuals' bodies processed the drugs. This finding could help explain why some people experience more severe effects from the drugs than others.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Insect-inspired super rubber moves toward practical uses in medicine
2. Toward a safer form of acetaminophen
3. New materials, progress toward an HIV vaccine, and more at meeting of crystallographers
4. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
5. Toward broad-spectrum antiviral drugs for common cold and other infections
6. NREL drives toward the future with fuel cell EVs
7. Engineered stem cell advance points toward treatment for ALS
8. A giant step toward miniaturization
9. The large-scale EU project EU BON: Towards integration with its global counterpart GEO BON
10. Towards more sustainable construction
11. Report: Water and Agriculture in Canada: Towards Sustainable Management of Water Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:5/19/2016)... ... May 19, 2016 , ... Anton Paar USA, located in Ashland, Virginia is ... complete. The new structure adds a third office building to the current facilities. ... 2.4 acres of land, along with office space adjacent to the previous main building. ...
(Date:5/19/2016)... Regen BioPharma, Inc ... announced today initiation of a preclinical development program ... cancer immunotherapeutic product leveraging its NR2F6 immunological checkpoint. ... generation of cord blood derived killer cells whose ... product in development will be a "universal donor" ...
(Date:5/18/2016)... The Biotech industry continues to face ... there are no opportunities ahead. Today, ActiveWallSt.com has on its ... THLD ), Seattle Genetics Inc. (NASDAQ: SGEN ), ... (NASDAQ: OPHT ). Sign up now to receive ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares gained 0.68%, ...
(Date:5/18/2016)... ... May 18, 2016 , ... Ryan Benton was diagnosed ... expectancy in the late teens to early twenties. DMD is a relatively common progressive ... the age of 22, Benton’s condition was critical. He met with the founder of ...
Breaking Biology Technology: